The clinical study evaluates the safety, tolerability and pharmacokinetics of the sublingual dexmedetomidine wafers in 14 healthy volunteers, says iX Biopharma.
iX Biopharma (SGX:42C
) has completed Phase 1 of its pharmacokinetic clinical study on the sublingual dexmedetomidine wafer it is developing.
The drug is being developed to treat dementia-related agitation, an unmet need and a condition where no drug treatment has been approved to-date.
